Summary & Overview
CPT 0566U: Episeek MPE Malignant Pleural Effusion Detection Test
CPT code 0566U designates the Episeek™ MPE (Malignant Pleural Effusion Detection Test), a proprietary laboratory test that uses qPCR to evaluate methylation changes across 13 DNA regions in pleural fluid and reports a qualitative result by algorithm. As a PLA code, 0566U is specific to Precision Epigenomics Inc.’s single test and is used when billing for that proprietary assay. Nationally, PLA codes like 0566U matter because they standardize reporting for unique commercial diagnostics and inform coverage and payment discussions for molecular tests that support cancer-related diagnosis or management.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for pleural fluid molecular testing, payer coverage considerations, and benchmarks relevant to proprietary molecular diagnostics. The publication summarizes how CPT PLA coding functions, the intended use of the Episeek™ MPE test, and the typical laboratory setting for specimen processing. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 0566U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to the Episeek™ MPE (Malignant Pleural Effusion Detection Test) developed by Precision Epigenomics Inc. The test analyzes pleural fluid using quantitative polymerase chain reaction (qPCR) to assess methylation changes in 13 DNA regions and delivers a qualitative result through a proprietary algorithm.
Service Type: Laboratory testing using targeted qPCR-based methylation analysis.
Typical Site of Service: Clinical laboratory or specialized molecular diagnostics laboratory processing pleural fluid specimens.
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves an adult presenting with a pleural effusion of unclear etiology identified on chest radiograph or chest CT. The treating clinician (pulmonologist, thoracic surgeon, or interventional radiologist) performs thoracentesis to obtain pleural fluid for diagnostic testing. When cytology and standard laboratory testing (cell count, chemistry, Gram stain/culture) are inconclusive for malignancy, the clinician sends pleural fluid for the Episeek™ MPE (Malignant Pleural Effusion Detection Test) to evaluate DNA methylation patterns in 13 genomic regions by quantitative PCR. The laboratory performs the proprietary assay and runs an algorithm to provide a qualitative result (e.g., positive/negative for methylation patterns associated with malignant pleural effusion). Typical sites of service include hospital-based laboratories, hospital outpatient departments, and independent clinical reference laboratories that process specimens received from inpatient or outpatient settings. The clinical workflow: patient evaluation → thoracentesis and specimen collection → standard pleural fluid studies and cytology → send additional aliquot to the lab performing the Episeek™ MPE (0566U) → laboratory analytic processing and algorithmic interpretation → result returned to ordering clinician for integration into diagnostic decision-making regarding malignant pleural effusion.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Original submission (no modifier) |